Sun Pharma to acquire oncology product from Novartis for $175 million; stock up 0.5%
"Odomzo gives us an opportunity to meaningfully expand our already established branded dermatology business and support our expansion into branded oncology with a launched brand," Kirti Ganorkar, Global Head Business Development at Sun Pharma, said.
BSE. Representational image. Pic: IANS